TRIP System Represses Transgene Translation in Viral Vector Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of therapeutic retroviral vectors is hindered by the adverse expression of proteins encoded by the transgene in production cells, which reduces vector titers and can impact cell viability and immune response, making it challenging to achieve high or moderate titers while maintaining effective expression in target cells.
Innovation Solution
The use of a heterologous translation control system, specifically the TRIP system, which employs an RNA-binding protein like tryptophan RNA-binding attenuation protein (TRAP) to repress the translation of the nucleotide of interest in viral vector production cells, preventing undesirable protein expression and maintaining vector production and functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the transgene is expressed in production cells to enable therapeutic gene delivery, then the therapeutic function is achieved, but vector titers are reduced and cell viability is impacted
Solution Approach 1:
The patent applies conditional expression systems that allow dynamic control of transgene expression based on cellular context. Promoters are engineered to be active only in target cells (e.g., tissue-specific promoters, inducible promoters) and not in production cells, enabling the system to adapt its behavior to different cellular environments and resolve the contradiction between therapeutic function and vector production.
Solution Approach 2:
The patent segments the expression control into separate functional modules: production phase (where transgene is silenced) and therapeutic phase (where transgene is expressed). This is achieved through promoter engineering, conditional transcription factors, or epigenetic control mechanisms that create distinct expression states in production versus target cells, allowing optimization of both vector titers and therapeutic efficacy.
2Reliability
If the transgene is expressed in production cells, then therapeutic gene delivery capability is established, but immune response is triggered
Solution Approach 1:
The patent employs preliminary anti-action by preemptively preventing transgene expression in production cells through promoter design, RNA interference, or epigenetic silencing mechanisms. This anticipatory control prevents the formation of transgene products that would otherwise trigger immune responses during vector production, while preserving full therapeutic functionality in target cells.
3Reliability
If strong promoters are used to drive transgene expression, then therapeutic expression level is increased, but vector production efficiency is reduced
Solution Approach 1:
The patent applies local quality by creating spatially differentiated expression control: strong therapeutic expression in target cells versus minimal or no expression in production cells. This is achieved through tissue-specific promoter elements, cell-type-specific transcription factor requirements, or epigenetic modifications that are established during vector production but only become active in the therapeutic context, allowing strong promoters to be used without compromising production efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases vector titers by up to 100-fold, minimizes immune response, and ensures the stability and functionality of viral vector particles, allowing for robust and persistent therapeutic gene expression in target cells.
Implementation Method 1
the binding site is capable of interacting with an RNA-binding protein such that translation of the nucleotide of interest is repressed or prevented in a viral vector production cell
Data Source
AI summary
The present invention relates to a nucleic acid sequence comprising a binding site operably linked to a nucleotide of interest, wherein the binding site is capable of interacting with an RNA-binding protein such that translation of the nucleotide of interest is repressed in a viral vector production cell.